Abstracts tagged "corticosteroids"

Abstract Number: 2604 • 2017 ACR/ARHP Annual Meeting
The Effect of Subcutaneous Belimumab on Corticosteroid Use in Patients with Systemic Lupus Erythematosus (SLE): A Phase 3, Randomized, Placebo-Controlled Study
Ronald F van Vollenhoven¹, April Thompson², Bonnie Pobiner², Joe Eastman², Anne Hammer², James Groark³ and Damon Bass³, ¹Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ²GSK Research Triangle Park, Research Triangle Park, NC, ³GSK Collegeville, Collegeville, PA
Background/Purpose: Reduced corticosteroid use is considered a key goal in SLE treatment. This concept of ‘steroid-sparing’, seen with intravenous (IV) belimumab based on cumulative steroid…
Abstract Number: 2906 • 2017 ACR/ARHP Annual Meeting
Use of Disease-Modifying Antirheumatic Drugs, Biologic Response Modifiers and Corticosteroids, and Subsequent Risk of Coccidioidomycosis Infection Among Medicare Beneficiaries
Dominick Sudano¹, C. Kent Kwoh², Lili Zhou³, Erin L. Ashbeck⁴ and Wei-Hsuan Lo-Ciganic⁵, ¹University of Arizona Arthritis Center, University of Arizona, Tucson, AZ, ²University of Arizona, Tucson, AZ, ³Department of Pharmacy, Practice and Science, University of Arizona, College of Pharmacy, Tucson, AZ, ⁴The University of Arizona Arthritis Center, Tucson, AZ, ⁵Department of Pharmacy, Practice and Science, College of Pharmacy, University of Arizona, Associate professor, TUCSON, AZ
Background/Purpose: Coccidioidomycosis (Cocci) is a fungal infection endemic to seven states in the US. Biologic response modifiers (BRMs) have been shown to increase the risk…
Abstract Number: 2956 • 2017 ACR/ARHP Annual Meeting
Evidence Based Recommendations for Corticosteroid Tapering/Discontinuation in New Onset Juvenile Dermatomyositis Patients from the Printo Trial
Gabriella Giancane¹, Claudio Lavarello¹, Angela Pistorio¹, Francesco Zulian¹, Bo Magnusson¹, Tadej Avcin¹, Fabrizia Corona¹, Valeria Gerloni², Serena Pastore¹, Roberto Marini¹, Silvana Martino¹, Anne Pagnier², Michel Rodiere¹, Christine Soler¹, Valda Stanevicha¹, Rebecca ten Cate³, Yosef Uziel¹, Jelena Vojinovic¹, Elena Fueri², Angelo Ravelli⁴, Alberto Martini⁵ and Nicolino Ruperto¹, ¹Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genoa, Italy, ²Istituto Giannina Gaslini - Pediatria II, Reumatologia - PRINTO, Genova, Italy, ³Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴University of Genova, IRCCS Istituto Giannina Gaslini, Genova, Italy, ⁵Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: At present no clear evidence based guidelines exist to standardize the tapering and discontinuation of corticosteroids (CS) in juvenile dermatomyositis (JDM). To provide evidence-based…
Abstract Number: 206 • 2017 ACR/ARHP Annual Meeting
Real World IGRA Testing in Rheumatology Practice
Paul DeMarco^1,2, Megan Bishop³, Ashling Smith⁴, Herbert S. B. Baraf^1,5, Andrew Gregory DeMarco⁶, Temitope Ademola⁷, Deborah Contreras⁸, Adalisa Enriquez RMA¹, Lisa Klein¹, Kayra Perez¹, Sandra Ventura¹, Janice Whyte-Whitworth¹, Vince Calhoun¹, Theresa Bass Goldman¹ and Alan K Matsumoto^1,9, ¹The Center for Rheumatology and Bone Research, Wheaton, MD, ²Division of Rheumatology, Department of Medicine, Georgetown University School of Medicine, Washington, DC, ³Clinical Trials, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁴2730 University Blvd West, Suite 306, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁵Department of Medicine, George Washington University School of Medicine, Washington, DC, ⁶Department of Biochemistry and Molecular Cellular Biology, Georgetown University Department of Biochemistry and Molecular Cellular Biology, Washington, DC, ⁷The Center for Rheumatology and Bone Research, Washington, DC, ⁸2730 University Boulevard West, Suite 306, The Center for Rheumatology and Bone Research, Wheaton, MD, ⁹Department of Medicine, Division of Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD
Background/Purpose: Mycobacterium tuberculosis (MTb) screening is routine for clinical trial protocols, & authorization for immunomodulators use by health insurances. Real world data is needed to…
Abstract Number: 787 • 2017 ACR/ARHP Annual Meeting
Prevalence of Relapses of Giant Cell Arteritis in Patients Treated with Corticosteroids: A Meta-Analysis
Alexandra Addario¹, Quitterie Reynaud^2,3, Maxime Samson⁴, Mathilde Francois³, Stéphane Durupt³, Francois Gueyffier¹, Michel Cucherat¹, Isabelle Durieu^2,5 and Jean-Christophe Lega^3,6, ¹Equipe Evaluation et Modélisation des Effets thérapeutiques, Lyon 1 University, Lyon, France, ²HESPER group, Lyon 1 University, Lyon, France, ³Department of Internal and Vascular Medicine, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ⁴Department of Internal Medicine and Clinical Immunolgy, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ⁵Department of Internal and Vascular, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ⁶Equipe Evaluation et Modélisation des Effets thérapeutiques, UMR CNR 5558, Lyon 1 University, Lyon, France
Background/Purpose: The relapse rate of giant cell arteritis (GCA) in the patients treated by corticosteroids (CS) varied widely in observational series and randomized trials. The…
Abstract Number: 795 • 2017 ACR/ARHP Annual Meeting
Characteristics and Treatment Outcomes of Giant Cell Arteritis with Large-Vessel Lesions in a Nationwide, Retrospective Cohort Study in Japan
Takahiko Sugihara¹, Hitoshi Hasegawa², Haruhito Uchida³, Hajime Yoshifuji⁴, Yoshikazu Nakaoka⁵, Yoshiko Watanabe⁶, Eisuke Amiya⁷, Masanori Konishi⁸, Yasuhiro Katsumata⁹, Yoshinori Komagata¹⁰, Taio Naniwa^11,12, Takahiro Okazaki¹³, Yoshiya Tanaka¹⁴, Tsutomu Takeuchi¹⁵, Masayoshi Harigai¹⁶, Yoshihiro Arimura¹⁷ and Mitsuaki Isobe^8,18, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, Japan, ³Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Osaka University Graduate School of Medicine, Osaka, Japan, ⁶First Department of Physiology, Kawasaki Medical School, Kurashiki, Japan, ⁷Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ⁸Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan, ⁹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁰First Dept. of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹¹Division of Rheumatology, Dept of Internal Medicine,, Nagoya City University Hospital, Nagoya, Japan, ¹²Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ¹³Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan, ¹⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ¹⁶Division of Epidemiology and Pharmacoepidemiology of Rheumatic Diseases, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ¹⁷First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, ¹⁸Sakakibara Heart Institute, Tokyo, Japan
Background/Purpose: Giant cell arteritis (GCA) often affects aorta or its branches, but it is unclear whether the large-vessel (LV) lesions are associated with treatment outcomes.…
Abstract Number: 819 • 2017 ACR/ARHP Annual Meeting
Risks of Non-Cardiovascular Corticosteroid Related Adverse Events and Cancer in Giant Cell Arteritis: A French Population-Based Cohort Study
Minh Phuong Do¹, Grégory Pugnet², Guillaume Moulis³, Gregory Guernec⁴, Maryse Lapeyre-Mestre⁵ and Laurent Sailler⁶, ¹Faculté de Médecine, Toulouse University, Laboratoire de Pharmacoepidemiologie, Equipe émergente,UMR INSERM 1027, Toulouse, France, ²Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, ³Internal Medicine, Toulouse University Hospital, Toulouse, France, ⁴Faculté de Médecine, Toulouse University, UMR INSERM 1027, Toulouse, France, ⁵UMR 1027, INSERM-University of Toulouse, Toulouse, France, ⁶Medecine Interne, CHU Toulouse, Toulouse, France
Background/Purpose: Corticosteroid related adverse events are a main concern in patients suffering from giant cell arteritis. Conflicting results are reported on this topic, recurrent events…
Abstract Number: 934 • 2017 ACR/ARHP Annual Meeting
Effectiveness of FX006 Intra-Articular Injection in Patients with Knee Osteoarthritis Who Present with and without Clinical Inflammation at Baseline: A Pooled Analysis of Data from 3 Double-Blind, Randomized, Parallel-Group Clinical Trials
Herbert S. B. Baraf¹, Christian Lattermann², Deryk G. Jones³, Philip G. Conaghan⁴, Joelle Lufkin⁵, James Johnson⁶, Scott Kelley⁵ and Neil Bodick⁵, ¹Center for Rheumatology and Bone Research, Wheaton, MD, ²University of Kentucky, Orthopaedic Surgery and Sports Medicine, Lexington, KY, ³Ochsner Sports Medicine Institute, New Orleans, LA, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Flexion Therapeutics, Inc., Burlington, MA, ⁶Summit Analytical, Denver, CO
Background/Purpose: Inflammation is a key contributor to osteoarthritis (OA).1 OA pain is mediated by interactions between inflammatory cytokines and other features including local tissue damage,…
Abstract Number: 1200 • 2017 ACR/ARHP Annual Meeting
Updating the Knee Osteoarthritis Intra-Articular Corticosteroid Meta-Analysis with Two Large Trials of Extended-Release Triamcinolone Acetonide (FX006) Versus Placebo
Philip G. Conaghan¹, Francis Berenbaum², Virginia B. Kraus³, James Johnson⁴ and Scott Kelley⁵, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Pierre & Marie Curie University, Saint-Antoine Hospital, Paris, France, ³Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, ⁴Summit Analytical, Denver, CO, ⁵Flexion Therapeutics, Inc., Burlington, MA
Background/Purpose: A recent meta-analysis concluded that intra-articular corticosteroids (IACS) for knee osteoarthritis (OA) may be associated with moderate improvement in pain compared with control treatment.1,2…
Abstract Number: 1313 • 2017 ACR/ARHP Annual Meeting
Oral Corticosteroid Use during Pregnancy and Risk of Preterm Birth in Women with Rheumatoid Arthritis
Kristin Palmsten¹, Gretchen Bandoli², Diana L Johnson¹, Ronghui Xu^3,4 and Christina D Chambers¹, ¹Department of Pediatrics, University of California, San Diego, La Jolla, CA, ²Pediatrics, University of California, San Diego, La Jolla, CA, ³Department of Family Medicine and Public Health, University of California, San Diego, La Jolla, CA, ⁴Department of Mathematics, University of California, San Diego, La Jolla, CA
Background/Purpose: There are limited data regarding gestational timing of oral corticosteroid (OCS) use during pregnancy and risk of preterm birth. The objective was to compare…
Abstract Number: 1442 • 2017 ACR/ARHP Annual Meeting
Corticosteroid Sparing Effect of Non-TNF Targeted Biologics, Rituximab, Abatacept and Tocilizumab in Common Practice: Data from 3183 Patients Enrolled in the French Society of Rheumatology Registries
Jacques-Eric Gottenberg¹, Jacques Morel², Arnaud Constantin³, Thomas Bardin⁴, Alain Cantagrel⁵, Bernard Combe², Maxime Dougados⁶, René-Marc Flipo⁷, Alain Saraux⁸, Thierry Schaeverbeke⁹, Jean Sibilia¹⁰, Martin Soubrier¹¹, Olivier Vittecoq^12,13, Gabriel Baron¹⁴, Elodie Perrodeau¹⁵, Philippe Ravaud¹⁴ and Xavier Mariette¹⁶, ¹CNRS, Immunopathologie et Chimie Thérapeutique/Laboratory of Excellence Medalis, Institut de Biologie Moléculaire et Cellulaire, Strasbourg, France, ²Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ³Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁴Clinique de Rhumatologie, Hopital Lariboisiere, Paris Cedex 10, France, ⁵Department of Rheumatology, Purpan Hospital, Toulouse III University, Toulouse, France, Toulouse, France, ⁶Rheumatology, Paris Descartes University, Paris, France, ⁷Rheumatology, Department of Rheumatology, CHU Teaching Hospital Lille, France., Lille, France, ⁸Rheumatology, Brest University Hospital, Brest, France, ⁹Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France, ¹⁰Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹¹Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹²INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ¹³Rheumatology Department and INSERM U 905, CHU Rouen, Rouen, France, ¹⁴Hôpital Hôtel Dieu, Paris, France, ¹⁵Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: Little is known regarding the corticosteroid sparing effect of non-TNF biologics in rheumatoid arthritis (RA). Objectives : To compare the corticosteroid sparing effect of…
Abstract Number: 1460 • 2017 ACR/ARHP Annual Meeting
Predictive Factors Associated with Successful Down-Titration of Biologics for Rheumatoid Arthritis Patients in Clinical Practice
Takaaki Komiya¹, Kaoru Minegishi-Takase², Natsuki Sakurai¹, Yuichiro Sato¹, Hideto Nagai³, Naoki Hamada³, Yumiko Sugiyama³, Naomi Tsuchida¹, Yutaro Soejima³, Yosuke Kunishita³, Hiroto Nakano³, Daiga Kishimoto³, Koji Kobayashi², Reikou Kamiyama³, Ryusuke Yoshimi³, Yukiko Asami³, Yohei Kirino³, Shigeru Ohno⁴ and Hideaki Nakajima³, ¹Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, ³Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁴Center for Rheumatic Disease, Yokohama City University Medical Center, Yokohama, Japan
Background/Purpose: Randomized clinical trials have shown that if a patient is in sustained remission, biological disease-modifying anti rheumatic drugs (bDMARDs) therapy can be tapered in…
Abstract Number: 93 • 2017 Pediatric Rheumatology Symposium
Corticosteroid Regimen Use in the Pilot Study of Consensus Treatment Plans for Induction Therapy in Childhood Proliferative Lupus Nephritis
Jennifer C. Cooper¹, B. Anne Eberhard², Marilynn Punaro³, Stacy P. Ardoin⁴, Hermine Brunner⁵, Joyce Hsu⁶, Linda Wagner-Weiner⁷, Marisa Klein-Gitelman⁸, Kelly A. Rouster-Stevens⁹, Laura E. Schanberg¹⁰, Emily von Scheven¹¹ and the CARRA Investigators, ¹Pediatrics, Divison of Rheumatology, University of California, San Francisco, San Francisco, CA, ²Cohen Children's Medical Center of New York, New Hyde Park, NY, ³Texas Scottish Rite Hospital for Children, Dallas, TX, ⁴Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH, ⁵Rheumatology, PRCSG, Cincinnati, OH, ⁶Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁷University of Chicago Hospital, Chicago, IL, ⁸Division of Rheumatology, Department of Pediatrics, Ann & Robert H. Lurie Children’s Hospital of Chicago/Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹Pediatric Rheumatology, Emory Children's Center, Atlanta, GA, ¹⁰Pediatrics, Duke Medical Center, Durham, NC, ¹¹Division of Rheumatology, Department of Pediatrics, University of California San Francisco, San Francisco, CA
Background/Purpose: Comparative data in the pediatric lupus nephritis (LN) population are lacking. To reduce treatment variability and facilitate comparative effectiveness studies, the Childhood Arthritis and…
Abstract Number: 2236 • 2016 ACR/ARHP Annual Meeting
Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study
Gihyun Myung¹, Winnie Nelson² and Maureen A. McMahon³, ¹Division of Rheumatology/Department of Internal Medicine, University of California-Los Angeles, Los Angeles, CA, ²Health Economics and Outcomes Research, Mallinckrodt Pharmaceuticals, Hampton, NJ, ³University of California-Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA
Background/Purpose: Repository corticotropin injection (RCI) may produce anti-inflammatory and immune-modulatory effects. This study examined the demographics of those who used RCI and the trends in…
Abstract Number: 2245 • 2016 ACR/ARHP Annual Meeting
Injectable Corticosteroid Use in Musculoskeletal Care Specialties
Gurjit S. Kaeley¹, Myint Thway¹ and Sunita Dodani², ¹Rheumatology, University of Florida College of Medicine, Jacksonville, Jacksonville, FL, ²Epidemiology, University of Florida, College of Medicine & College of Public Health and Health Professions, Gainesville, Jacksonville, FL
Background/Purpose: Injectable corticosteroids (IC) are widely used for joint and soft tissue injections. Although four main types of preparations are available, there is sparse evidence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].